Abstract
BackgroundInfliximab (IFX) and adalimumab (ADL) are biological drugs used in the treatment of rheumatoid arthritis (RA), spondyloarthropathy (SpA), and juvenile idiopathic arthritis (JIA). Development of antidrug antibodies (ADAb) may lead...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
